SecBot SecBot
PRESS-RELEASE ·Filed Mar 12, 2026

RLMD

Relmada Therapeutics
NEUTRAL
Impact 3/10
Horizondays Processed8mo ago WireGlobeNewswire
Press release · Earnings
Actionable Insight • Neutral

Traders should await the actual earnings release and management commentary on March 19 for any material updates on cash runway, trial progress, or funding plans. Absence of data makes this pre-announcement low impact.

DirectionNeutral
Confidencehigh
Horizondays

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$6.15
T+0 close · Mar 12, 2026 · via day close
Latest settled
−3.25%
T+60 · $5.95
Vs SPY
−13.95%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Mar 12 $6.15entry
  2. T+1 · 8mo ago −3.90%α −3.30% · $5.91
  3. T+5 · 8mo ago +1.63%α +2.60% · $6.25
  4. T+20 · 7mo ago +18.54%α +16.56% · $7.29
  5. T+60 · 5mo ago −3.25%α −13.95% · $5.95
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Relmada Therapeutics announced plans to host a conference call on March 19, 2026, to discuss its Q4 and full-year 2025 financial results. The press release contains no actual financial data, guidance, or material business updates, serving only as a notification of the upcoming earnings event.

Key Facts

  • Relmada Therapeutics will host a conference call on March 19, 2026, at 4:30 PM ET to discuss Q4 and full-year 2025 financial results.
  • No financial results, guidance, or material operational updates were disclosed in the press release.
  • The company remains in clinical-stage development with lead candidates NDV-01 and sepranolone in mid-stage trials.

Financial Impact

None disclosed, no financial figures released

Risk Factors

  • Lack of disclosed financials increases information asymmetry ahead of the call.
  • Clinical-stage biotech with no near-term revenue, stock remains highly speculative.

Market Snapshot

Exchange
Nasdaq

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3254447

Track record

11 reports on RLMD

Performance horizon

2 of 3 bullish or bearish reports moved the stock their way by T+20. Best: +38.81% at T+60 after the May 13, 2026 report. 2 of 3 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Bearish 5/10 Entry $3.54 Now $3.61 −1.98% settles Dec 15
  2. Nov 16, 2026today 8-K Neutral 3/10 Entry $4.16 Now $3.61 −13.23% settles Dec 15
  3. Nov 12, 20264d ago 8-K Neutral 4/10 Entry $4.21 Now $3.61 −14.25% settles Dec 14
  4. Sep 11, 20269w ago Insider Cluster Bullish 6/10 Entry $4.52 to $3.39 Now $3.61 −20.13% ▼ −25.00% −26.87% vs SPY
  5. May 13, 202626w ago S-3ASR Bearish 6/10 Entry $7.42 to $6.65 Now $3.61 +51.35% ▲ +10.38% +9.52% vs SPY
  6. May 12, 202626w ago 8-K Neutral 4/10 Entry $7.49 to $6.52 Now $3.61 −51.80% ▼ −12.95% −12.34% vs SPY
  7. Apr 17, 202630w ago DEFA14A Neutral 3/10 Entry $7.37 to $6.34 Now $3.61 −51.02% ▼ −13.98% −18.18% vs SPY
  8. Apr 3, 202632w ago S-3 Neutral 3/10 Entry $6.90 to $7.41 Now $3.61 −47.68% ▲ +7.39% −1.59% vs SPY
  9. Mar 19, 202634w ago Press Release Bullish 8/10 Entry $6.07 to $7.37 Now $3.61 −40.53% ▲ +21.42% +12.10% vs SPY
  10. Mar 12, 202635w ago Press Release Neutral 3/10 Viewing Entry $6.15 to $7.29 Now $3.61 −41.30% ▲ +18.54% +16.56% vs SPY
Showing 10 of 11

US Market Status

Market Closed · Opens in 6h 38m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Mar 12, 2026